APO Research
Talk to an analyst

APO RESEARCH · REPORT

CAR-T Cellular Immunotherapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CAR-T Cellular Immunotherapy Market Outlook and Growth Opportunities 2026

2 January 2026192 pages

Choose your research edition.

Industry ResearchCAR-T Cellular Immunotherapy Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal CAR-T Cellular Immunotherapy Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal CAR-T Cellular Immunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CAR-T Cellular Immunotherapy Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal CAR-T Cellular Immunotherapy Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global CAR-T Cellular Immunotherapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CAR-T Cellular Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CAR-T Cellular Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CAR-T Cellular Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CAR-T Cellular Immunotherapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CAR-T Cellular Immunotherapy market include Novartis, Gilead Sciences, Fosun Kite Biotechnology and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CAR-T Cellular Immunotherapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CAR-T Cellular Immunotherapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CAR-T Cellular Immunotherapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CAR-T Cellular Immunotherapy market.

CAR-T Cellular Immunotherapy Segment by Company

Novartis

Gilead Sciences

Fosun Kite Biotechnology

Bristol-Myers Squibb

CAR-T Cellular Immunotherapy Segment by Type

Allogeneic

Autologous

CAR-T Cellular Immunotherapy Segment by Application

Hospital

Pharmacy

Other

CAR-T Cellular Immunotherapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global CAR-T Cellular Immunotherapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CAR-T Cellular Immunotherapy key companies, revenue, market share, and recent developments.

3. To split the CAR-T Cellular Immunotherapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CAR-T Cellular Immunotherapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CAR-T Cellular Immunotherapy significant trends, drivers, influence factors in global and regions.

6. To analyze CAR-T Cellular Immunotherapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CAR-T Cellular Immunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CAR-T Cellular Immunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CAR-T Cellular Immunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CAR-T Cellular Immunotherapy industry.

Chapter 3: Detailed analysis of CAR-T Cellular Immunotherapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CAR-T Cellular Immunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CAR-T Cellular Immunotherapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CAR-T Cellular Immunotherapy Industry Trends Table 2. CAR-T Cellular Immunotherapy Industry Drivers Table 3. CAR-T Cellular Immunotherapy Industry Opportunities and Challenges Table 4. CAR-T Cellular Immunotherapy Industry Restraints Table 5. Global CAR-T Cellular Immunotherapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CAR-T Cellular Immunotherapy Revenue Share by Company (2021-2026) Table 7. Global CAR-T Cellular Immunotherapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CAR-T Cellular Immunotherapy Key Company Manufacturing Base & Headquarters Table 9. Global CAR-T Cellular Immunotherapy Company, Product Type & Application Table 10. Global CAR-T Cellular Immunotherapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CAR-T Cellular Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Allogeneic Table 15. Significant Companies of Autologous Table 16. Global CAR-T Cellular Immunotherapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global CAR-T Cellular Immunotherapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global CAR-T Cellular Immunotherapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global CAR-T Cellular Immunotherapy Sales Value Share by Type (2021-2026) Table 20. Global CAR-T Cellular Immunotherapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Pharmacy Table 23. Significant Companies of Other Table 24. Global CAR-T Cellular Immunotherapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global CAR-T Cellular Immunotherapy Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global CAR-T Cellular Immunotherapy Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global CAR-T Cellular Immunotherapy Sales Value Share by Application (2021-2026) Table 28. Global CAR-T Cellular Immunotherapy Sales Value Share by Application (2027-2032) Table 29. Global CAR-T Cellular Immunotherapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global CAR-T Cellular Immunotherapy Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global CAR-T Cellular Immunotherapy Sales Value Share by Region (2021-2026) Table 32. Global CAR-T Cellular Immunotherapy Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global CAR-T Cellular Immunotherapy Sales Value Share by Region (2027-2032) Table 34. Global CAR-T Cellular Immunotherapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global CAR-T Cellular Immunotherapy Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global CAR-T Cellular Immunotherapy Sales Value Market Share by Country (2021-2026) Table 37. Global CAR-T Cellular Immunotherapy Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global CAR-T Cellular Immunotherapy Sales Value Market Share by Country (2027-2032) Table 39. Novartis Company Information Table 40. Novartis Business Overview Table 41. Novartis CAR-T Cellular Immunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Novartis CAR-T Cellular Immunotherapy Product Portfolio Table 43. Novartis Recent Development Table 44. Gilead Sciences Company Information Table 45. Gilead Sciences Business Overview Table 46. Gilead Sciences CAR-T Cellular Immunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Gilead Sciences CAR-T Cellular Immunotherapy Product Portfolio Table 48. Gilead Sciences Recent Development Table 49. Fosun Kite Biotechnology Company Information Table 50. Fosun Kite Biotechnology Business Overview Table 51. Fosun Kite Biotechnology CAR-T Cellular Immunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Fosun Kite Biotechnology CAR-T Cellular Immunotherapy Product Portfolio Table 53. Fosun Kite Biotechnology Recent Development Table 54. Bristol-Myers Squibb Company Information Table 55. Bristol-Myers Squibb Business Overview Table 56. Bristol-Myers Squibb CAR-T Cellular Immunotherapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bristol-Myers Squibb CAR-T Cellular Immunotherapy Product Portfolio Table 58. Bristol-Myers Squibb Recent Development Table 59. Research Programs/Design for This Report Table 60. Authors List of This Report Table 61. Secondary Sources Table 62. Primary Sources List of Figures Figure 1. CAR-T Cellular Immunotherapy Product Image Figure 2. Global CAR-T Cellular Immunotherapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CAR-T Cellular Immunotherapy Market Size (2021-2032) & (US$ Million) Figure 4. Global CAR-T Cellular Immunotherapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Allogeneic Image Figure 8. Autologous Image Figure 9. Global CAR-T Cellular Immunotherapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global CAR-T Cellular Immunotherapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global CAR-T Cellular Immunotherapy Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Pharmacy Image Figure 14. Other Image Figure 15. Global CAR-T Cellular Immunotherapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global CAR-T Cellular Immunotherapy Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global CAR-T Cellular Immunotherapy Sales Value Share by Application (2021-2032) Figure 18. Global CAR-T Cellular Immunotherapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global CAR-T Cellular Immunotherapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America CAR-T Cellular Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 21. North America CAR-T Cellular Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe CAR-T Cellular Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 23. Europe CAR-T Cellular Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific CAR-T Cellular Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific CAR-T Cellular Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America CAR-T Cellular Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 27. South America CAR-T Cellular Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa CAR-T Cellular Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa CAR-T Cellular Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Allogeneic
  • Autologous
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Novartis
  • Gilead Sciences
  • Fosun Kite Biotechnology
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CAR-T Cellular Immunotherapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CAR-T Cellular Immunotherapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CAR-T Cellular Immunotherapy Market Dynamics
  1. 2.1 CAR-T Cellular Immunotherapy Industry Trends
  2. 2.2 CAR-T Cellular Immunotherapy Industry Drivers
  3. 2.3 CAR-T Cellular Immunotherapy Industry Opportunities and Challenges
  4. 2.4 CAR-T Cellular Immunotherapy Industry Restraints
3 CAR-T Cellular Immunotherapy Market by Company
  1. 3.1 Global CAR-T Cellular Immunotherapy Company Revenue Ranking in 2025
  2. 3.2 Global CAR-T Cellular Immunotherapy Revenue by Company (2021-2026)
  3. 3.3 Global CAR-T Cellular Immunotherapy Company Ranking (2024-2026)
  4. 3.4 Global CAR-T Cellular Immunotherapy Company Manufacturing Base and Headquarters
  5. 3.5 Global CAR-T Cellular Immunotherapy Company Product Type and Application
  6. 3.6 Global CAR-T Cellular Immunotherapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CAR-T Cellular Immunotherapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CAR-T Cellular Immunotherapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CAR-T Cellular Immunotherapy Market by Type
  1. 4.1 CAR-T Cellular Immunotherapy Type Introduction
  2. 4.1.1 Allogeneic
  3. 4.1.2 Autologous
  4. 4.2 Global CAR-T Cellular Immunotherapy Sales Value by Type
  5. 4.2.1 Global CAR-T Cellular Immunotherapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global CAR-T Cellular Immunotherapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global CAR-T Cellular Immunotherapy Sales Value Share by Type (2021-2032)
5 CAR-T Cellular Immunotherapy Market by Application
  1. 5.1 CAR-T Cellular Immunotherapy Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global CAR-T Cellular Immunotherapy Sales Value by Application
  6. 5.2.1 Global CAR-T Cellular Immunotherapy Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global CAR-T Cellular Immunotherapy Sales Value by Application (2021-2032)
  8. 5.2.3 Global CAR-T Cellular Immunotherapy Sales Value Share by Application (2021-2032)
6 CAR-T Cellular Immunotherapy Regional Value Analysis
  1. 6.1 Global CAR-T Cellular Immunotherapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CAR-T Cellular Immunotherapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global CAR-T Cellular Immunotherapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global CAR-T Cellular Immunotherapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CAR-T Cellular Immunotherapy Sales Value (2021-2032)
  7. 6.3.2 North America CAR-T Cellular Immunotherapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CAR-T Cellular Immunotherapy Sales Value (2021-2032)
  10. 6.4.2 Europe CAR-T Cellular Immunotherapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CAR-T Cellular Immunotherapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CAR-T Cellular Immunotherapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CAR-T Cellular Immunotherapy Sales Value (2021-2032)
  16. 6.6.2 South America CAR-T Cellular Immunotherapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CAR-T Cellular Immunotherapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CAR-T Cellular Immunotherapy Sales Value Share by Country, 2025 VS 2032
7 CAR-T Cellular Immunotherapy Country-level Value Analysis
  1. 7.1 Global CAR-T Cellular Immunotherapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CAR-T Cellular Immunotherapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global CAR-T Cellular Immunotherapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global CAR-T Cellular Immunotherapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CAR-T Cellular Immunotherapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CAR-T Cellular Immunotherapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CAR-T Cellular Immunotherapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis CAR-T Cellular Immunotherapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis CAR-T Cellular Immunotherapy Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences CAR-T Cellular Immunotherapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences CAR-T Cellular Immunotherapy Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 Fosun Kite Biotechnology
  14. 8.3.1 Fosun Kite Biotechnology Company Information
  15. 8.3.2 Fosun Kite Biotechnology Business Overview
  16. 8.3.3 Fosun Kite Biotechnology CAR-T Cellular Immunotherapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Fosun Kite Biotechnology CAR-T Cellular Immunotherapy Product Portfolio
  18. 8.3.5 Fosun Kite Biotechnology Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb CAR-T Cellular Immunotherapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb CAR-T Cellular Immunotherapy Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst